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Abstract Introduction Despite new treatment options tar-
geted at its three main pathogenic pathways, prognosis of
idiopathic pulmonary arterial hypertension has remained
dismal, with 3-year survival rates around 70 %. Antiprolif-
erative agents have emerged as a new therapeutic concept.
However, they may exert their effects only after a prolonged
period of time. Case description Herein we present a patient
who, despite being on a triple targeted drug therapy including
high-dose intravenous prostanoids, still had severe pul-
monary hypertension. After 4 years treatment with the
tyrosine kinase inhibitor imatinib, the patient could be
weaned from intravenous prostanoids and attained a persis-
tent hemodynamic normalization. Conclusions Antiprolif-
erative agents might be a promising new class of drugs in
pulmonary arterial hypertension. However, the occurrence
of unexpected side effects like the increased incidence of
subdural hematomas, has led to the recommendation that at
present such an off-label use is strongly discouraged, and that
further studies elucidating the risk/benefit ratio of tyrosine
kinase inhibitors are clearly needed.
Keywords Imatinib  Pulmonary arterial
hypertension  Treatment
Impacts on practice
• Antiproliferative agents should for the time being not
be used off-label in pulmonary arterial hypertension.
• The risk/benefit ratio of tyrosine kinase inhibitors in
arterial hypertension remains to be established.
Introduction
Presently, there are three classes of approved therapies for
idiopathic pulmonary arterial hypertension (IPAH), namely
endothelin receptor antagonists, phosphodiesterase-5 inhibi-
tors, and prostanoids. Nonetheless, the prognosis of patients
with IPAH has remained dismal, with 3-year survival rates
around 70 %.
Although experimentally some antiproliferative proper-
ties have been attributed to all of these three drug classes,
their main treatment effect is vasodilation. However,
except in very early disease, vasodilators remain to be a
symptomatic treatment. Only recently, the antiproliferative
approach has gained clinical interest because of the
emergence of the tyrosine kinase inhibitors. By the first
experimental proof of concept study in the rat monocro-
taline model, Schermuly et al. [1] could show that the
antiproliferative agent imatinib, which targets mainly the
pathogenically important platelet-derived growth factor
[2], was able to reverse pulmonary hypertension. Shortly
thereafter, the same group started imatinib in a patient
already receiving all three classes of the therapeutic agents
mentioned above but refusing lung transplantation [3]. Six
months later, there was a dramatic improvement in
hemodynamics, 6-min walking distance (6MWD) and
functional class.
In the meanwhile, the phase II trial [4] and the subsequent
large randomized trial (IMPRES) [5] could demonstrate that
imatinib significantly improves hemodynamics within a
period of 6 months.
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About 2 years after the first case report by Ghofrani
et al. [3], we commenced imatinib treatment in selected
patients on an off-label use basis. Herein we present a
patient suffering from severe IPAH, who could be suc-
cessfully weaned from intravenous prostanoids within a
period of 5 years and attained a persistent hemodynamic
normalization.
Case description
This 37-years-old woman was diagnosed with IPAH in
October 2006. She then had a mean pulmonary artery
pressure of 68 mmHg, a cardiac output of 1.9 L/min/m2,
and a pulmonary vascular resistance (PVR) of 2,261
dyn  seconds  cm-5 (See Table 1). Chronic thrombo-
embolic, left heart and pulmonary diseases were exclu-
ded by negative ventilation/perfusion scan, normal
pulmonary artery wedge pressure, and lung function
testing. Family history was non-revealing and there were
no other diseases known to be associated with PAH. She
then was treated with bosentan 125 mg bid., sildenafil
50 mg tid., inhaled iloprost 100 lg daily, oral antico-
agulation and diuretic therapy. As depicted in Fig. 1, the
6MWD temporarily improved from 310 to 410 m.
However, within 1 year her condition deteriorated dra-
matically, and in October 2007 the patient became
almost bed-ridden. Other causes for this clinical course
such as pulmonary embolism could be excluded. Her
PVR still was very high (1,506 dyn  seconds  cm-5).
Treatment with continuous intravenous iloprost was
commenced, and its dose was up-titrated to 500 lg per
day. This resulted in an improvement in her 6MWD up to
444 m until February 2008. Her hemodynamics, how-
ever, were still seriously impaired with a PVR over 1,000
dyn  seconds  cm-5. Hence, we started an off-label
treatment with imatinib 400 mg per day. Six months
later, her pulmonary vascular resistance had decreased to
300 dyn  seconds  cm-5.
During the subsequent 3 years of imatinib therapy, the
patient further improved her 6MWD and remained stable in
functional class II. Except for an episode of central venous
catheter infection there were no complications, adverse
events or disease-related events. Since by April 2010 her
pulmonary hemodynamics almost normalized, we decided
to reduce gradually intravenous iloprost until complete stop
by August 2011. Two month later the pulmonary hemo-
dynamics were completely normal.
One year later, the patient still is completely stable on
bosentan and sildenafil. Echocardiography showed a nor-
mal size of the right atrium and the right ventricle, and a
normal right heart function, i.e. a fractional area contrac-
tion of 42 % (normal [25) and a tricuspid annular systolic
plane excursion of 23 mm (normal [17).
Discussion
This is to the best of our knowledge the first patient suf-
fering from severe IPAH, who could be weaned from
intravenous prostanoids, and completely normalized her
pulmonary hemodynamics and right ventricular function,
remaining solely on continued dual oral targeted drug
treatment. We speculate that this normalization can most
probably be attributed to long-term imatinib therapy.
So far, there are only two case series including 17 adults
suffering from IPAH, in whom intravenous prostanoids
could be discontinued [6, 7]. However, it has to be
emphasized that all these patients in fact were switched
from prostanoids to the new targeted oral or inhaled ther-
apies becoming available at that time. None of them was
already receiving targeted treatments at the start of wean-
ing from intravenous prostanoids. After all, it is noticeable
that three patients maintained a normal PVR after transition
from intravenous to modern oral or inhaled therapy.
Since the first randomized trial in IPAH 1996, there is an
ongoing discussion, what kind of treatment goal is realistic
in this otherwise devastating disease. Unfortunately, until
Table 1 Clinical and hemodynamic data over time
October 2006 October 2007 February 2008 April 2010 October 2011
6-Min walking distance (m) 310 70 444 550 580
WHO functional class IV IV II II II
Mean pulmonary artery pressure (mmHg) 68 64 53 27 23
Cardiac index (L/min/m2) 1.1 1.7 2.6 4.7 5.7
Pulmonary vascular resistance (dyn  seconds  cm-5) 2,261 1,506 1,023 259 163
Pulmonary artery wedge pressure (mmHg) 14 10 5 6 7
Right atrial pressure (mmHg) 16 19 Not done 4 5
Mixed venous oxygen saturation (%) 37 29 48 72 69
N-terminal pro–brain natriuretic peptide (pg/mL) Not done 1,204 1,822 90 69
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now, aiming at a normalization of pulmonary hemody-
namics has remained to be a search for the holy grail. None
of the two largest series of IPAH patients on long-term
epoprostenol has explicitly reported on any patient with
normal hemodynamics on last follow-up [8, 9]. The lower
95 % confidence intervals of mean pulmonary artery
pressures in these two series were 32 [8] and 40 mmHg [9],
respectively. The same was the case even in prognostically
favorable patients on long-term calcium-channel blockers
with a lower 95 % confidence interval of mean pulmonary
artery pressure of 34 mmHg [10].
There are only limited data on the long-term benefits of
imatinib [11]. Foreseeably, because of its mode of action a
potential breakthrough effect like in our patient might be
expected to occur only after some years of tratment. Souza
et al. [12] have described two cases, who were on imatinib
treatment over a period of 3 years. Both exhibited a sus-
tained hemodynamic improvement. However, at that time
their hemodynamics still were far from being normal.
Although not being provable, we strongly believe that
the leading effect explaining this extraordinary clinical
course of our patient has to be ascribed to a reverse
remodeling effect of imatinib. In the rat monocrotaline
model, Schermuly et al. [1] found a marked increase in cell
proliferation in the pulmonary resistance vessels. This
could be explained by a lack of apoptosis in the hyper-
tensive animals comparable to the non-exposed control
animals. Treatment with imatinib resulted a significantly
increase in apoptosis in the vessel walls, going along with a
reduction of the proliferation rate and a near normal vessel
morphology. Moreover, these researchers could elegantly
show, that platelet-derived growth factor, a known potent
inhibitor of apoptosis, which in fact has shown to be
increased in the vasculature of patients with IPAH [2],
seems to act as the main anti-apoptotic factor in this con-
text. While it was entirely absent in the control animals, it
massively increased in the monocrotaline-exposed rats.
This increase could almost completely be abrogated by
treatment with imatinib.
It could be argued that also the current three targeted
therapeutic modalities might have some antiproliferative
effect, especially the prostanoids. This has been shown at
least in the experimental setting. In humans, however, such
a therapeutic effect has never been described so far. Of
course, the significance of histological examinations of
lungs at autopsy or after explantation is hampered by a
negative selection bias including only most severe cases.
However, there is one interesting study by Achcar et al.
[13], who examined explanted lung from 9 patients who
had been treated with prostacyclin for a mean of
40 months, and compared them with lungs from 11 patients
who had a similar hemodynamic compromise but other
treatments than prostanoids. There was not only no dif-
ference in vascular remodeling between the two groups, but
even a non-significant trend towards a more pronounced
medial thickness and a higher number of plexiform lesions
in the prostanoid-treated group. In this context, would like
to add another interesting report of a patient, who had been
Fig. 1 Clinical course of the
patient. PVR pulmonary
vascular resistance, SvO2 mixed
venous saturation, proBNP
N-terminal pro–brain natriuretic
peptide, 6-MWD 6-minute
walking distance
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on prostacylin for 18 years, and died because of colonic
cancer. At autopsy she still showed an extensive prolifer-
ative vasculopathy [14]. Hence, we do not believe that the
prostanoid contributed relevantly to the restoration of
normal hemodynamics and right ventricular function in our
patient.
At this point, a word of caution on the use of imatinib
has to be made. The authors of the IMPRES study reported
in September 2011 [15], that there were two cases of
subdural hematoma while on imatinib during the random-
ized trial phase, and in addition, another six cases were
observed in the extension study, summing up to an inci-
dence of 4.2 % per patient year [11]. When we became
aware of this serious complication possibly attributable to
imatinib in combination with oral anticoagulation, we
immediately took two measures. Firstly, we confronted all
current and subsequent patients treated with imatinib with a
range of potential morbidity and mortality rates due to
subdural hematoma and the potential benefits of imatinib
(unpublished data). All patients were willing to take the
worst risk–benefit scenario and gave a written informed
consent. Secondly, we decided to keep the INR around 2.0.
May be due to the latter measure, we did not observe any
case of subdural hematoma over a period of currently
around 30 patient-years (unpublished data).
Notwithstanding, it has to be stressed that we use i-
matinib off-label, and this treatment is not in accordance
with the current guidelines on management of pulmonary
hypertension (4th World Symposium and ERS/ESC
guidelines) as well as the recommendations made at the last
world symposium on pulmonary hypertension, held in Nice
2013, and the statement made by the authors of the
IMPRES trial [5] and an accompanying editorial [16]. The
increased incidence of subdural hematomas during imati-
nib treatment may suggest a poor benefit/risk ratio in PAH.
Hence, these authorities stated that until further data are
available, the off-label use of imatinib for this indication is
strongly discouraged.
Furthermore, tyrosine kinase inhibitors should generally
be used with caution in PAH since they may have other
unexpected side effects. This is exemplified by reports on
the development of PAH during treatment with dasatinib
[17]. Hence, we fully agree with Marc Humbert’s call for
‘‘a better understanding of the pathways involved in the
efficacy and safety aspects of imatinib in order to design
more targeted and better tolerated agents in the field of
personalized PAH medicine’’ [16].
Conclusions
In conclusion, we presume that the antiproliferative effects
of long-term imatinib therapy induced by the clearly
described apoptosis of pulmonary vascular smooth muscle
cells [1] were the leading effect explaining the clinical
course of the current patient, who could be weaned from
intravenous prostanoids and attained normal pulmonary
hemodynamics parameters. However, we would like to
emphasize that at present such an off-label use is strongly
discouraged by the authorities until more data on the risk/
benefit ratio of tyrosine kinase inhibitors in patients with
PAH become available.
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